The Prix Galien awards were held this week in London.
This year saw the introduction of a new award category for Real World Evidence (RWE). Five drugs and their RWE initiatives were shortlisted for this award. Excitingly for pH Associates, two of the five were for projects designed, delivered and analysed by pH Associates. As you can imagine we were on tenterhooks on Wednesday night!
We’re delighted to confirm that Astellas was the winner of this prestigious award, thanks to some innovative work around the introduction and use of its antibiotic Dificlir®, which was launched in 2012 and also received a commendation at UK Prix Galien 2014.
Outlining the rationale behind its win, Professor Sir Michael Rawlins, Chair of the UK Prix Galien judges said: “A unique series of local service evaluations were conducted in 2013–2014 to evaluate the impact of Dificlir introduction on the NHS. The evaluation, studied in real world settings, included investigating its effects on service delivery, the management of CDI and its costs, primarily to inform local decision-making. Results indicated the very significant contribution that Dificlir’s use can make to tackling the major public health problems of antimicrobial resistance through targeted antibiotic therapy and infection control.”
pH worked with the team at Astellas and a number of KOLs to design and conduct a series of service evaluations in partnership with local Trusts. We are pleased that the programme was also supported by a number of other OPEN Health companies in the communication of results: Succinct Medical Communications, LEC, and Reynolds MacKenzie.
More information can be found on the Prix Galien website.
If you are interested in learning more about this project, or how pH Associates can help you create game-changing real world evidence, do not hesitate to contact us.
Sam Oliver, Joint MD - SamOliver@phassociates.com
Amanda Pulfer - AmandaPulfer@phassociates.com
or call us on: 01628 481112